John Trzupek is an accomplished biotechnology industry executive who brings to Abata nearly 15 years of experience in the areas of drug discovery, strategy, finance, operations and entrepreneurship.
Prior to Abata, John was chief business officer of KSQ Therapeutics, responsible for corporate strategy, finance, operations and business development. In this capacity, John was instrumental in closing the company’s major strategic collaborations with Takeda and CRISPR Therapeutics, and in securing the company’s $80M Series C financing round. Before that, he held several business and scientific roles at Pfizer, most recently as director of strategy, inflammation and immunology, where he founded and led a highly successful interdisciplinary drug discovery innovation unit that garnered investment in new therapeutic and research areas. In his prior work as a scientist at Pfizer, John was the co-inventor of multiple product candidates that reached the clinic. Notably, he was a primary contributor to the design and discovery of PF-06650833, a novel small molecule drug candidate being studied for the treatment of autoimmune disease.
John holds an MBA with high honors as an Amy and Richard F. Wallman Scholar from the University of Chicago Booth School of Business, where he concentrated in finance. He holds a Ph.D. in organic chemistry from The Scripps Research Institute as a National Defense Science and Engineering predoctoral fellow, and completed his postdoctoral training at Memorial Sloan-Kettering Cancer Center.